← FDA DRUG APPROVALS

FDA ANDA · ANDA064145

CEFACLOR

Sponsor: TEVA

APPLICATION
ANDA064145
TYPE
ANDA
ORIGINAL APPROVAL
1996-06-24
LATEST ACTION
2000-01-24
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Discontinued

Products

CEFACLORDiscontinued
CEFACLOR EQ 500MG BASE · CAPSULE · ORAL
CEFACLORDiscontinued
CEFACLOR EQ 250MG BASE · CAPSULE · ORAL

Approval history

2000-01-24Manufacturing (CMC) · Supplement 4AP
1999-04-30Labeling · Supplement 3AP
1998-11-04Labeling · Supplement 2AP
1997-10-23Labeling · Supplement 1AP
1996-06-24OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →